Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Myocardial Infarction and Elevated Platelet Counts: A Multicenter Comparative Analysis of Ischemic Outcomes.

Rev Cardiovasc Med · 2026 · PMC13227351 · PMID 42238619

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The fact that highly significant reductions in MACCE, all-cause mortality, and cardiac mortality were still observed despite this probable dilution of treatment effect strongly supports a robust biological advantage of ticagrelor in this high-thrombotic-risk population and validates the observed benefits.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.